14.16
+3.81%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About ArriVent BioPharma
From its filings with the US Securities and Exchange Commission
ArriVent BioPharma is based in Newtown Square, Pennsylvania and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker AVBP. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $166.3m. At that date it held total assets of $333.2m and shareholders' equity of $307.2m.
We are a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. We seek to utilize our team’s deep drug development experience to maximize the potential of our lead product candidate, firmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, including ARR-217 (MRG007), through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors. Firmonertinib is currently being evaluated in multiple clinical trials across a range of epidermal growth factor receptor (EGFR) mutations (EGFRm) in non-small cell lung cancer (NSCLC). We are conducting a pivotal Phase 3 clinical trial of firmonertinib in treatment naive, or first-line, patients with locally advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations and a pivotal Phase 3 clinical trial of firmonertinib in first-line patients with locally advanced or metastatic EGFRm NSCLC with P-loop and-alpha-c-helix compressing (PACC) mutations. We are conducting a Phase 1 clinical trial of ARR-217 in patients with unresectable locally advanced or metastatic solid tumors.
Quoted from its 10-K, filed 5 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 26 Jan 2024
- Employees
- 77
- Website
- arrivent.com ↗
- Head office
- 18 CAMPUS BLVD., NEWTOWN SQUARE, PA, 19073-3269
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Dr. Zhengbin YaoChairman of the Board, President, Chief Executive Officer, since 2021$2.4m
- Mr. Winston KungChief Financial Officer, Treasurer$1.8m
- Ms. Robin LachapelleChief Operating Officer$960,986
- Mr. James KastenmayerGeneral Counsel, Secretary
- Ms. Kristine PetersonLead Independent Director$278,525
- Dr. Stuart LutzkerDirector, President of Research and Development, since 2021$985,967
- Dr. James HealyIndependent Director
- Dr. John HohnekerIndependent Director$476,943
- Mr. Chris NoletIndependent Director$364,790
- Dr. Merdad ParseyIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 25
- Environment
- 25
- Social
- 40
- Governance
- 10
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- ArriVent BioPharma Inc's Furmonertinib targets multiple EGFR mutations including exon 20 insertions for NSCLC treatment.
- The company focuses on clinical-stage biopharmaceutical development with a pipeline of novel therapeutics.
- ArriVent BioPharma Inc employs 77 full-time employees in Newtown Square, Pennsylvania.
Weaknesses
- The company's lead candidate Furmonertinib is still investigational and requires further clinical trials.
- ArriVent BioPharma Inc has only 77 employees, indicating limited operational scale.
- The firm's initial focus on solid tumors may restrict broader market reach in oncology.
Opportunities
- Furmonertinib's potential to address unmet medical needs in NSCLC patients with EGFR mutations.
- The growing market for targeted cancer therapies in the US healthcare sector.
- Expansion opportunities in the oncology segment for antibody drug conjugates development.
Threats
- Competition from established biopharmaceutical companies in the oncology space.
- Regulatory hurdles for approval of Furmonertinib in the US market.
- Potential delays in clinical trials affecting Furmonertinib's development timeline.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.